Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.

Trial Details

NCT ID
NCT06158828
Phase
PHASE1 / PHASE2
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Rabbit Anti thymocyte globulin
  • Busulfan
  • Fludarabine
  • Thiotepa
  • Melphalan
  • TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • High risk acute myeloid leukemia (AML) in either:
  • Complete remission (CR) defined by \< 5% marrow blasts by morphology in the context of hematological recovery (ANC ≥ 0.5× 10\^9/L, platelet count ≥…
  • Morphological leukemia free state (MLFS) defined by the absence of hematological recovery and \< 5% marrow blasts by morphology
  • Patients must further meet one of the below for inclusion into the study:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →